News | July 09, 2025
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
The biosimilar Ustekinumab has been developed and manufactured by the company
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Tofacitinib Tablets, 5 mg and 10 mg had annual sales of US $900 million in the United States (IQVIA MAT December 2022)
Subscribe To Our Newsletter & Stay Updated
